Tekla Life Sciences Investors Total Liabilities
Tekla Life Sciences Investors total liabilities. Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has total liabilities worth $2.40 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HQL asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tekla Life Sciences Investors (1996–2025)
Total liabilities of Tekla Life Sciences Investors from 1996 to 2025. This chart illustrates how Tekla Life Sciences Investors's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Tekla Life Sciences Investors's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Tekla Life Sciences Investors Competitors by Total Liabilities
The table below lists competitors of Tekla Life Sciences Investors ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Laurent-Perrier
PA:LPE
|
France | €491.23 Million |
|
Vibhavadi Medical Center Public Company Limited
BK:VIBHA
|
Thailand | ฿11.86 Billion |
|
Turaco Gold Ltd
AU:TCG
|
Australia | AU$3.42 Million |
|
Abacus Group
AU:ABG
|
Australia | AU$1.04 Billion |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
China | CN¥12.42 Billion |
|
Founders Metals Inc.
V:FDR
|
Canada | CA$10.30 Million |
|
ANGLO ASIAN MINING
F:A4A
|
Germany | €154.09 Million |
|
AmRest Holdings SE
MC:EAT
|
Spain | €1.93 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Tekla Life Sciences Investors's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tekla Life Sciences Investors balance sheet assets.
Liquidity & Leverage Metrics
Tekla Life Sciences Investors Total Liabilities Ratios Explained
Tekla Life Sciences Investors total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tekla Life Sciences Investors's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual total liabilities of Tekla Life Sciences Investors from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $1.73 Million | +94.24% |
| 2024-09-30 | $888.61K | +33.23% |
| 2023-09-30 | $666.96K | -96.04% |
| 2022-09-30 | $16.82 Million | +56.56% |
| 2021-09-30 | $10.75 Million | +1705.34% |
| 2020-09-30 | $595.18K | -78.93% |
| 2019-09-30 | $2.82 Million | -5.14% |
| 2018-09-30 | $2.98 Million | +50.27% |
| 2017-09-30 | $1.98 Million | -25.50% |
| 2016-09-30 | $2.66 Million | -46.95% |
| 2015-09-30 | $5.01 Million | +564.49% |
| 2014-09-30 | $754.55K | +42.34% |
| 2013-09-30 | $530.12K | +31.00% |
| 2012-09-30 | $404.67K | -59.53% |
| 2011-09-30 | $1.00 Million | -81.48% |
| 2010-09-30 | $5.40 Million | -67.27% |
| 2009-09-30 | $16.50 Million | +415.63% |
| 2008-09-30 | $3.20 Million | +190.91% |
| 2007-09-30 | $1.10 Million | -59.26% |
| 2006-09-30 | $2.70 Million | +170.00% |
| 2005-09-30 | $1.00 Million | -23.08% |
| 2004-09-30 | $1.30 Million | -50.00% |
| 2003-09-30 | $2.60 Million | +766.67% |
| 2002-09-30 | $300.00K | -62.50% |
| 2001-09-30 | $800.00K | -42.86% |
| 1998-09-30 | $1.40 Million | +600.00% |
| 1997-09-30 | $200.00K | -66.67% |
| 1996-09-30 | $600.00K | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more